6-K
GSK plc (GSK)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2026
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 26 May 2026, London UK
Admission to trading
In conformity with PRM 1.6.4R, GSK plc notifies the market that ordinary shares of 31¼ pence each ('Ordinary Shares') have been admitted to trading as set out in the table below. The Ordinary Shares have been admitted to trading under existing block listing admissions of Ordinary Shares in connection with the "GlaxoSmithKline plc Share Save Plan 2022".
| 1a | Issuer name | GSK plc |
|---|---|---|
| 1b | Issuer LEI | 5493000HZTVUYLO1D793 |
| 2 | Regulated market on which the securities have been admitted to<br>trading | London Stock Exchange - Main Market |
| 3 | Name, type and ISIN of the securities | Ordinary Shares of 31¼ pence each<br><br><br><br><br><br>ISIN: GB00BN7SWP63 |
| 4 | Number of further securities admitted to trading covered<br>by this notification | 45,273 |
| 5 | Total number of securities admitted to trading following<br>admission | 4,316,221,551 |
| 6 | Fungibility | Fully fungible with existing Ordinary Shares |
| 7 | Date range covered by the notification | 27 March 2026 - 22 May 2026 |
| 8 | Prospectus information | N/A |
V A Whyte
Company Secretary
26 May 2026
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: May<br>26, 2026 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |